Put companies on watchlist
Medartis Holding AG
ISIN: CH0386200239
WKN: A2JGBF
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Medartis Holding AG · ISIN: CH0386200239 · EQS - adhoc news (32 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1154353
11 December 2020 06:59AM

Medartis appoints Dirk Kirsten as Chief Financial Officer and EMB member


EQS Group-Ad-hoc: Medartis Holding AG / Key word(s): Personnel
Medartis appoints Dirk Kirsten as Chief Financial Officer and EMB member

11-Dec-2020 / 06:59 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


Medartis Holding AG
Hochbergerstrasse 60E
CH-4057 Basel

PRESS RELEASE

Medartis appoints Dirk Kirsten as Chief Financial Officer

Basel, Switzerland, 11 December 2020 - The Board of Directors of Medartis Holding AG (SIX: MED) has appointed Dirk Kirsten as new Chief Financial Officer and Member of the Executive Management Board. He will join Medartis as of 1 march 2021 and will succeed Dominique Leutwyler, who has decided to leave the company.

In his future role as CFO and Member of the Executive Management Board of Medartis, Dirk Kirsten will be responsible for all matters of internal and external group financial management, as well as for the group's M&A projects, thus actively supporting further growth and envisaged portfolio expansions.

As a proven financial expert with broad industry experience, Dirk Kirsten (1968) has a strong track record in international management, corporate finance and M&A and held various senior management positions in the medtech, pharmaceutical and healthcare sectors. These included the roles as CFO of Nobel Biocare (2008-2013), Group Treasurer of Syngenta (2004-2008) and Head Group Funding & Capital Markets of Roche Holding (2002-2004). Prior to that, he worked with global investment banks, where he specialized in healthcare transactions. In 2013, Dirk Kirsten founded his own advisory boutique focusing on M&A, private equity as well as start-up financing and business development. Dirk Kirsten is a Swiss and German citizen. He holds a PhD in Management & Economics from the University of Cologne and participated in the international MBA program of the London Business School.

Over the last 20 years, Dominique Leutwyler has made a significant contribution as CFO in building the pillars of Medartis on its way from a start-up to a listed company with broad international presence. He established and further developed the group's finance functions, supply chain and ICT operations and was additionally responsible for the set-up of its production infrastructure and its thirteen subsidiaries as well as for various beneficial M&A activities. He also lead-managed Medartis' successful IPO in 2018. He will remain in his position until the 2020 full-year results publication on 10 March 2021. The Board of Directors and Executive Management Board regret Dominique Leutwyler's decision and are grateful to him for his extensive and successful contributions in building Medartis to its current strengths. Medartis wishes him every success for his future.

Contact
Patrick Christ
Head Corporate Services
Medartis Holding AG
Phone: +41 61 633 34 70
patrick.christ@medartis.com

About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world's leading manufacturers and providers of medical devices for surgical fixation of bone fractures for upper and lower extremities as well as for the craniomaxillofacial region. Medartis employs around 630 individuals across its 13 locations, with products offered in over 50 countries globally. Medartis is committed to providing surgeons and operating theatre personnel with the most innovative titanium implants and instruments as well as best in class service. For more information, please visit www.medartis.com.

Disclaimer
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained herein or of the views given or implied.



End of ad hoc announcement
Language: English
Company: Medartis Holding AG
Hochbergerstrasse 60E
4057 Basel
Switzerland
Phone: +41 61 633 34 34
Fax: +41 61 633 34 00
E-mail: info@medartis.com
Internet: www.medartis.com
ISIN: CH0386200239
Valor: 38620023
Listed: SIX Swiss Exchange
EQS News ID: 1154353

 
End of Announcement EQS Group News Service

1154353  11-Dec-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1154353&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Medartis Holding AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.